Editas Medicine, Inc. - Common Stock (NQ:EDIT)

3.385 -0.285 (-7.77%)

Streaming Delayed Price Updated: 1:37 PM EDT, Jul 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Editas Medicine, Inc. - Common Stock

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Why Editas Medicine Stock Charged Higher in January ↗

February 02, 2023

The genome-editing company's shares spiked following a definitive agreement with Shoreline Biosciences last month.

Via The Motley Fool

Analyst Initiates Coverage On This Peer Lagging Gene-Editing Stock ↗

February 01, 2023

Via Benzinga

Expert Ratings for Editas Medicine ↗

February 01, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For February 1, 2023 ↗

February 01, 2023

Via Benzinga

Why Shares of Editas Medicine Jumped This Week ↗

January 26, 2023

It's been a seesaw month for the clinical-stage gene-editing biotech.

Via The Motley Fool

Shoreline Biosciences Acquires Editas' iNK Cell Franchise, Related Gene Editing Technologies ↗

January 19, 2023

Via Benzinga

Analyst Expectations for Editas Medicine's Future ↗

January 10, 2023

Via Benzinga

Why Editas Medicine Stock Is Sliding Today ↗

January 09, 2023

The gene-editing pioneer announced a big shake-up with its research and development programs.

Via The Motley Fool

7 CRISPR Stocks With the Best Long-Term Potential ↗

January 30, 2023

CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve.

Via InvestorPlace

How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?

January 25, 2023

Five biotechs have already issued layoffs in 2023. Many seem to have good potential, but time will tell if the shifts create the value analysts anticipate.

Via MarketBeat

Topics Workforce

Editas Medicine and Shoreline Biosciences Enter into Definitive Agreement for Shoreline to Acquire Editas’ iNK Cell Franchise and Related Gene Editing Technologies

January 19, 2023

From Editas Medicine, Inc.

Via GlobeNewswire

3 CRISPR Stocks That Will Make You Filthy Rich in 10 Years ↗

January 18, 2023

CRISPR could be revolutionary, leading us to put together this list of CRISPR stocks that will make you rich in 10 years.

Via InvestorPlace

Analyst Ratings for Editas Medicine ↗

December 06, 2022

Via Benzinga

Why Shares of Editas Medicine Dropped 15.5% in November ↗

December 05, 2022

The biotech's shares plummeted after it paused a key clinical trial.

Via The Motley Fool

Why Editas Medicine's Shares Are Falling Thursday ↗

November 17, 2022

The company shelved a clinical trial for one of its lead therapies.

Via The Motley Fool

Editas Medicine Announces Strategic Updates and Portfolio Reprioritization

January 09, 2023

From Editas Medicine, Inc.

Via GlobeNewswire

Editas Medicine to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 04, 2023

From Editas Medicine, Inc.

Via GlobeNewswire

Precigen's Overnight Cell Manufacturing Technology Could Offer Advanced AML Patients The Option Of Promising CAR-T Therapy ↗

December 08, 2022

-Clinical Data Due Next Week at ASH-

Via Benzinga

2 Beaten-Down Stocks to Watch Closely Next Year ↗

December 06, 2022

These biotechs could skyrocket in 2023, but only if they can execute their plans.

Via The Motley Fool

Editas Medicine Touts Positive Safety, Efficacy Data From Two Sickle Cell Disease Patients ↗

December 06, 2022

Via Benzinga

Editas Medicine Announces Positive Safety and Efficacy Data from the First Two Patients Treated in the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease

December 06, 2022

From Editas Medicine, Inc.

Via GlobeNewswire

Editas Medicine to Host Virtual Event to Highlight Initial Clinical Data from the RUBY Trial of EDIT-301 for Severe Sickle Cell Disease

December 01, 2022

From Editas Medicine, Inc.

Via GlobeNewswire

Where Will Editas Medicine Be in 1 Year? ↗

November 20, 2022

The company could continue lagging the market for a while.

Via The Motley Fool

Gene Editing Stock's Prospects Cut In Half By Analyst, Citing Limited Value In Retina Treatment ↗

November 18, 2022

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 18, 2022 ↗

November 18, 2022

Upgrades

Via Benzinga

Palo Alto To Surge Around 38%? Plus This Analyst Predicts $65 For Helmerich & Payne ↗

November 18, 2022

Barclays raised the price target on Palo Alto Networks, Inc. (NASDAQ: PANW) from $200 to $215. Barclays analyst Saket Kalia maintained an Overweight rating on the stock. Palo Alto Networks shares fell...

Via Benzinga

Intuit To $490? Here Are 5 Other Price Target Changes For Friday ↗

November 18, 2022

Barclays cut Intuit Inc. (NASDAQ: INTU) price target from $502 to $490. . Barclays analyst Raimo Lenschow maintained an Overweight rating on the stock. Intuit shares fell 3% to close at $381.88 on...

Via Benzinga

Gap To Rally 18%? Plus This Analyst Slashes PT On Super League Gaming By 50% ↗

November 18, 2022

Telsey Advisory Group boosted the price target on The Gap, Inc. (NYSE: GPS) from $10 to $15. Gap shares rose 5.6% to close at $12.71 on Thursday.

Via Benzinga

Nasdaq Down 60 Points; Alibaba Posts Upbeat Q2 Earnings ↗

November 17, 2022

U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping around 60 points on Thursday.

Via Benzinga

Why Inotiv Shares Dipped 57%; Here Are 76 Biggest Movers From Yesterday ↗

November 18, 2022

Gainers Satixfy Communications Ltd. (NYSE: SATX) jumped 96.4% to settle at $51.70 on Thursday.

Via Benzinga

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.